Optical biometry is the most precise

Article

Optical biometry provides more repeatable and precise measurements of biometric parameters in highly myopic eyes, states a recent study.

Optical biometry provides more repeatable and precise measurements of biometric parameters in highly myopic eyes, states a recent study.

Dr Peiyang Shen et al., Division of Preventive Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China, compiled a comparative evaluation on optical biometry (OLCR), partial coherence interferometry (PCI) applanation ultrasound biometry in highly myopic eyes.

Biometric measurements were recorded in patients with a spherical equivalence (SE) of -6.00 D or higher and an axial length (AL) of more than 25.0 mm. OLCRS was used to obtain AL and anterior chamber depth (ACD) and compared to the results obtained using PCI and applanation A-scan ultrasound. Bland-Altman analyses were used to evaluate repeatability.

The coefficient of variations (CoVs) for OLCR, PCI and applanation ultrasound were 0.06%, 0.07%, and 0.20%, respectively. ACD was recorded at 0.29 mm, 0.53 mm and 0.51 mm, respectively. Mean radius of corneal curvature was the most similar between OLCR and PCI, with a limit of agreement of 0.12 mm.

The AL and ACD measurements obtained by optical biometry were more precise and repeatable, compared to measurements obtained from applanation biometry.

The abstract can be viewed in the latest issue of the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.